Dalgleish Angus
Division of Cellular and Molecular Medicine, St George's University of London, Cranmer Terrace, London, SW17 0RE, UK.
IDrugs. 2007 Jul;10(7):463-7.
Cancer vaccines have been developed using a wide range of technologies, yielding agents ranging from nonspecific immunostimulants through to highly technical peptide- and DNA-based candidates. There are many technical challenges involved in even the most basic decisions in vaccine development, such as the choice of antigen, formulation, adjuvant, route of delivery and schedule. However, as discussed in this feature review, the tumor itself may pose the greatest technical challenge, particularly with regard to escaping the immune response. Strategies to overcome this challenge are discussed.
癌症疫苗已通过多种技术研发出来，产生的制剂范围从非特异性免疫刺激剂到高技术的基于肽和DNA的候选疫苗。即使在疫苗研发中最基本的决策，如抗原选择、配方、佐剂、给药途径和时间表等方面，也存在许多技术挑战。然而，正如本专题综述中所讨论的，肿瘤本身可能构成最大的技术挑战，特别是在逃避免疫反应方面。本文讨论了克服这一挑战的策略。
